How is oral isotretinoin prescribed for the treatment of acne vulgaris? Results from a UK Dermatology Clinical Trials Network (UKDCTN) and British Dermatological Nursing Group (BDNG) survey of health professionals.
Clin Exp Dermatol
; 48(1): 20-23, 2023 Jan 20.
Article
in En
| MEDLINE
| ID: mdl-36669181
ABSTRACT
We undertook a survey of UK healthcare professionals through the UK Dermatology Clinical Trials Network and British Dermatological Nursing Group to understand clinicians' routine practice of prescribing oral isotretinoin for treatment of acne vulgaris. We also wanted to understand clinicians' experiences and views on prescribing low daily dose regimens. Overall, the survey showed that clinicians adopted a patient-centred approach when deciding isotretinoin dosing. The rationale for using a low-dose regimen varied, but was focused on patient wellbeing during treatment. Some clinicians were concerned that use of a low-dose regimen could be less effective and lead to longer treatment durations. The survey results will be useful to inform a clinical trial investigating the effectiveness and safety of low daily dose isotretinoin for the treatment of acne.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Acne Vulgaris
/
Dermatologic Agents
/
Dermatology
Limits:
Humans
Country/Region as subject:
Europa
Language:
En
Journal:
Clin Exp Dermatol
Year:
2023
Document type:
Article
Affiliation country:
Reino Unido